Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ACST [NASD]
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own- Shs Outstand103.99M Perf Week-5.41%
Market Cap109.19M Forward P/E- EPS next Y-0.06 Insider Trans- Shs Float49.20M Perf Month-19.23%
Income- PEG- EPS next Q- Inst Own- Short Float0.23% Perf Quarter-25.00%
Sales0.36M P/S306.30 EPS this Y- Inst Trans- Short Ratio0.25 Perf Half Y-49.28%
Book/sh0.24 P/B4.37 EPS next Y33.30% ROA- Target Price6.25 Perf Year-52.70%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.94 - 4.20 Perf YTD-16.00%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-75.00% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.70% ATR0.06
Employees- Current Ratio- Sales Q/Q-93.30% Oper. Margin- RSI (14)33.69 Volatility9.09% 5.32%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.15 Prev Close1.04
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume443.64K Price1.05
Recom2.00 SMA20-8.58% SMA50-13.72% SMA200-46.92% Volume71,000 Change0.96%
15-Apr-14 08:57AM  Activist Trying To Unlock A Potential 65% Upside In Neptune at Seeking Alpha -8.11%
01-Apr-14 02:24PM  Neptune & Acasti Give Update on Patent Litigations With Enzymotec GlobeNewswire
08:27AM  Acasti Pharma: An Undervalued Biotech With A Potential Best-In-Class Omega-3 Drug at Seeking Alpha
18-Mar-14 09:41PM  4 Stocks Under $10 to Trade for Breakouts at TheStreet
21-Feb-14 10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha
10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High
14-Feb-14 09:52AM  Neptune and Acasti Provide Update on Patent Litigations With Enzymotec GlobeNewswire
09:40AM  Acasti and Neptune Provide Update on Patent Litigations with Enzymotec GlobeNewswire
07-Feb-14 08:00AM  Acasti Announces Closing of CAD$2.15 Million Private Placement GlobeNewswire
06-Feb-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet
03:15PM  5 Stocks Under $10 Set to Soar
21-Jan-14 11:46AM  Neptune Erecting A Moat In Omega-3; Shares Undervalued at Seeking Alpha
11:46AM  Neptune Erecting A Moat In Omega-3; Shares Undervalued
14-Jan-14 07:30AM  Acasti Announces Third Quarter Results GlobeNewswire
07:30AM  Acasti Announces Third Quarter Results
11-Jan-14 08:34AM  While Amarin Continues To Go Rancid, Neptune Will Soar at Seeking Alpha
08:34AM  While Amarin Continues To Go Rancid, Neptune Will Soar
09-Jan-14 07:30AM  FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial GlobeNewswire
07:30AM  FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial
19-Dec-13 07:30AM  Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors GlobeNewswire
07:30AM  Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
17-Dec-13 08:45AM  Neptune, Acasti reach patent settlement and license pact with Aker BioMarine theflyonthewall.com
08:45AM  Neptune, Acasti reach patent settlement and license pact with Aker BioMarine
08:30AM  Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement GlobeNewswire
16-Dec-13 06:07PM  Nasdaq stocks posting largest volume increases AP -8.70%
13-Dec-13 06:03PM  Nasdaq stocks posting largest volume increases AP +11.29%
10-Dec-13 05:01PM  Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month at Seeking Alpha
05:01PM  Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month
03-Dec-13 10:14AM  Acasti Announces Closing of US$23 Million Underwritten Offering of Units GlobeNewswire
10:14AM  Acasti Announces Closing of US$23 Million Underwritten Offering of Units
02-Dec-13 06:03PM  Nasdaq stocks posting largest volume increases AP
29-Nov-13 05:54PM  Nasdaq stocks posting largest volume increases AP
27-Nov-13 06:11PM  Nasdaq stocks posting largest volume increases AP -13.67%
09:22AM  InPlay: Acasti Pharma prices public offering of 16 mln units of Acasti at $1.25 per Unit, each Unit consisting of one Class A share and one Common Share purchase warrant of Acasti Briefing.com
09:19AM  Acasti Announces Pricing of US$20 Million Offering of Units GlobeNewswire
09:19AM  Acasti Announces Pricing of US$20 Million Offering of Units
26-Nov-13 04:04PM  InPlay: Acasti Pharma commences public offering of units of Acasti, each Unit consisting of one Class A share and one Common Share purchase warrant of Acasti; size not disclosed Briefing.com
04:01PM  Acasti Announces Proposed Offering of Units GlobeNewswire
04:01PM  Acasti Announces Proposed Offering of Units
11-Nov-13 08:31AM  InPlay: Acasti Pharma completes PK IND submission Briefing.com +5.24%
08:30AM  Acasti Completes PK IND Submission GlobeNewswire
05-Nov-13 08:30AM  Reed V. Tuckson, M.D. Joins Acasti's Board of Directors GlobeNewswire
29-Oct-13 08:32AM  InPlay: Acasti Pharma strengthens its IP portfolio; US patent application allowed by USPTO and granted in South Africa Briefing.com
08:30AM  Acasti Strengthens Its IP Portfolio GlobeNewswire
15-Oct-13 08:00AM  Acasti Announces Second Quarter Results GlobeNewswire
02-Oct-13 09:50AM  InPlay: Acasti Pharma and Neptune Technologies (NEPT) announce patent infringement settlements reached; NEPT grants a royalty bearing license on its patent (shares halted) Briefing.com +5.96%
09:45AM  Patent Infringement Settlements Reached GlobeNewswire
08:59AM  InPlay: ACST and NEPT halted, news pending Briefing.com
13-Sep-13 06:02PM  Nasdaq stocks posting largest volume increases AP
12-Sep-13 06:02PM  Nasdaq stocks posting largest volume increases AP
11-Sep-13 06:02PM  Nasdaq stocks posting largest volume increases AP +5.45%
10-Sep-13 06:02PM  Nasdaq stocks posting largest volume increases AP
09-Sep-13 06:02PM  Nasdaq stocks posting largest volume increases AP +5.10%
06-Sep-13 06:04PM  Nasdaq stocks posting largest volume increases AP +8.05%
05-Sep-13 06:03PM  Nasdaq stocks posting largest volume increases AP
13-Aug-13 07:46PM  4 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet
08:49AM  Acasti announces positive phase 2 open label clinical trial result at theflyonthewall.com
08:41AM  InPlay: Acasti Pharma announces 'positive' Phase II open label clinical trial results; primary objective was met: achieved a statistically significant triglyceride reduction as compared to Standard of Care; No serious adverse events were re Briefing.com
08:40AM  Acasti Announces Positive Phase II Open Label Clinical Trial Results GlobeNewswire
31-Jul-13 08:05AM  InPlay: Acasti Pharma signs manufacturing agreement for CaPre clinical material Briefing.com
08:00AM  Acasti Signs Manufacturing Agreement GlobeNewswire
15-Jul-13 08:00AM  Acasti Announces First Quarter Results GlobeNewswire
12-Jul-13 10:43PM  Neptune Announces Issuance of Shares Under Previously Announced Royalty Prepayment Agreement That Increases Its Equity Participation in Acasti Pharma Inc. GlobeNewswire
09-Jul-13 02:28PM  Acasti Pharma: Increasing Investor Interest And Volatility Likely Cometh at Seeking Alpha
05:10AM  Small-Cap Biotechs With Blockbuster Potential: Hugh Cleland at Seeking Alpha
03-Jul-13 05:38PM  Five 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
05:38PM  5 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
28-Jun-13 08:00AM  Acasti Reports Results of Annual and Special Meeting GlobeNewswire
07-Jun-13 01:04PM  ACASTI PHARMA INC. Financials EDGAR Online Financials
22-May-13 08:00AM  Acasti Announces Fiscal 2013 Results and Provides Update on Status of Clinical Trials GlobeNewswire -6.37%
15-Apr-13 08:00AM  The U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation Based on Neptune & Acasti Complaint GlobeNewswire
03-Apr-13 03:58AM  Krill Oil's Omega-3s And CaPre: Brought To You By Acasti at Seeking Alpha
26-Mar-13 11:36AM  3 Speculative Healthcare Companies With High Levels Of Insider Ownership - Part III at Seeking Alpha
19-Mar-13 08:01AM  InPlay: Acasti Pharma presents preliminary data moving forward with clinical strategy; CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-w Briefing.com -11.67%
08:00AM  Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy GlobeNewswire
14-Mar-13 08:00AM  Neptune to Present at the Annual ROTH Conference GlobeNewswire +5.73%
27-Feb-13 12:59AM  Amarin: The More You Know The Fishier It Gets at Seeking Alpha
19-Feb-13 07:19AM  3 Speculative Healthcare Companies With Very High Insider Ownerships at Seeking Alpha
31-Jan-13 08:00AM  Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing GlobeNewswire
30-Jan-13 08:00AM  Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others GlobeNewswire
29-Jan-13 06:29PM  Speculative Quasi-Biotech Neptune Off To A Strong Start In 2013 at Seeking Alpha -5.66%
24-Jan-13 08:00AM  Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization GlobeNewswire +5.69%
18-Jan-13 12:37PM  Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity at Seeking Alpha
15-Jan-13 08:00AM  Acasti Pharma Reports Its Third Quarter Results GlobeNewswire
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.